[SSRI-Research] Lilly says gets European approval for urinary drug [SSRI/Duloxetine disguised ONCE AGAIN]

[Guest guest]

> SSRI-Research

> Sat, 14 Aug 2004 11:03:51 -0400

> [sSRI-Research] Lilly says gets European

> approval for urinary drug [sSRI/Duloxetine disguised

> ONCE AGAIN]

>

>

> [-- Lilly is so corrupt.... can you imagine that

> duloxetine was approved for

> urinary incontinence???? And, it's approved ONLY

> for WOMEN. How many new

> suicides will it take to get this drug off the

> market? Lilly is the most

> evil of all. ]

>

>

> Reuters

> UPDATE - Lilly says gets European approval for

> urinary drug

> Friday August 13, 11:19 am ET

> http://biz./rc/040813/health_lilly_3.html

>

> (Adds details, updates share price, paragraphs 8-9)

>

> NEW YORK, Aug 13 (Reuters) - Eli Lilly and Co.

> (NYSE:LLY - News) on Friday

> said European regulators had approved its

> experimental medicine for moderate

> to severe stress urinary incontinence in women.

>

> People with the most common form of urinary

> incontinence accidentally leak

> urine due to physical activities, even sneezing and

> coughing. The pill,

> called Yentreve, is the first widely approved

> medicine in Europe to treat

> the condition.

>

> Lilly said the form of incontinence affects one in

> seven women over the age

> of 20 but relatively few men, so it was tested only

> in women.

>

> Yentreve contains the same active ingredient as

> Lilly's Cymbalta depression

> medicine approved earlier this month in the United

> States and still awaiting

> approval in Europe. Its chemical name is duloxetine.

>

> It works by maximizing the presence in the brain of

> two messenger chemicals,

> serotonin and norepinephrine.

> Wall Street expects Yentreve to be approved by U.S.

> regulators next year. It

> will be co-marketed in Europe and the United States

> by German drugmaker

> Boehringer Ingelheim.

>

> Lilly, however, will exclusively market sister drug

> Cymbalta in the United

> States.

>

> Some industry analysts expect Cymbalta and Yentreve

> to generate eventual

> combined peak annual sales of over $2 billion, a

> much-needed boon for Lilly

> after sales of its former top-selling

> antidepressant, Prozac, plunged in the

> face of generic competition.

>

> Shares of Lilly were up 51 cents, or 0.8 percent, at

> $62.57 in morning trade

> on the New York Stock Exchange.

>

>

> 2004 Reuters Limited. All rights

> reserved. Republication or

> redistribution of Reuters content is expressly

> prohibited without the prior

> written consent of Reuters. Reuters shall not be

> liable for any errors or

> delays in the content, or for any actions taken in

> reliance thereon.